Phase 1/2 Trial of APB-102, Gene Therapy for Familial ALS, Cleared to Open

Phase 1/2 Trial of APB-102, Gene Therapy for Familial ALS, Cleared to Open

294366

Phase 1/2 Trial of APB-102, Gene Therapy for Familial ALS, Cleared to Open

Clearance was given to open a Phase 1/2 trial evaluating APB-102, a potential gene therapy for amyotrophic lateral sclerosis (ALS) patients who carry mutations in the SOD1 gene, its developer Apic Bio announced. The trial is scheduled to begin later this year or early next year, following U.S. Food and Drug Administration (FDA) approval of its design as detailed in an investigational new drug (IND) application. “FDA IND clearance for our drug candidate APB-102 to treat SOD1 ALS is a…

You must be logged in to read/download the full post.